Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer

Investigational New Drugs

Volumn 20, Issue 4, 2002, Pages 413-417

  Amato, Robert J ^a   Perez, Cherie ^b   Pagliaro, Lance ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Irofulven; Kidney cancer; Phase II; Renal cell carcinoma

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; FLUOROURACIL; ILLUDIN S; IRINOTECAN; IROFULVEN; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA BINDING; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CANCER; KIDNEY CELL; MALE; METASTASIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; SESQUITERPENES;

EID: 0036830077     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020649827173     Document Type: Article

References (22)

1. Landis SH, Murray T, Bolden S, et al.: Cancer statistics. 1999. CA Cancer J Clin 49:8-31, 1999
2. Stadler WM, Vogelzang NJ: Low dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22:67-73, 1995
3. Hawkins MJ: Immunotherapy with high-dose interleukin 2, in Vogelzang NJ, Scardino PT, Shipley WU, et al. (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams and Wilkins, pp 242-247, 1996
4. Minasian LM, Motzer RJ, Gluck L, et al.: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
5. Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272-1278, 1998
6. McMorris TC, Kelner MJ, Wang W, et al.: Hydroxymethylacylfulvene (HMAF), an illudin derivative with superior antitumor properties. J Natl Prod 59(9):896-899, 1996
7. Woynarowski JM, Napier C, Koester SK, et al: Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF. MGI-114). Biochem Pharmacol 54:1181-1193, 1997
8. Herzig MCS, Arnett B, MacDonald JR et al.: Uptake and macromolecular binding of 6-hydroxymethylacylfulvene (HMAF, MGI-114) in a leukemia cell line. CEM (abstract) Proc Am Assoc Cancer Res 39:66, 1998
9. Kelner MJ, McMorris TC, Estes L, et al.: Efficacy of acylfulvene illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: Retention of activity against various mdr pheno-types and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells. Cancer Res 55(21):4936-4940, 1995
10. MacDonald JR, Muscoplat CC, Dexter DL et al: Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57(2):279-283, 1997
11. th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam. 1998
12. Kelner MJ, McMorris TC, Estes LA, et al.: Efficacy of MGI114 in the myeloid leukemia HL60/MRI xenograft model (abstract). Proc Am Assoc Cancer Res 39:227, 1998
13. th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1998
14. Kelner MJ, McMorris TC, Taetle R: HMAF (MGI-114) has antitumor activity in the mdrt/gp 170-positive human MV522 metastatic lung carcinoma xenograft (abstract). Proc Am Assoc Cancer Res 38:220, 1997
15. Eckhardt SG, Baker SD, Weiss GR, et al.: A phase 1 and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI-114 in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 17:233a, 1998
16. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
17. th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1998
18. Barrera H, MacDonald J, Hilsenbeck S, et al.: In vitro antitumor activity of MGI-114 in combination with topotecan, taxol, cisplatin, etoposide, or gemcitabine against pediatric tumor cell lines (abstract). Proc Am Assoc Cancer Res 39:527 (#3588), 1998
19. Marty J, MacDonald J, Mangold G, et al.: Evidence of synergistic antitumor activity with MGI-114 in combination with irinotecan (ITN) or 5-fluorouracil (5-FU) against a human colon tumor xenograft model (abstract). Proc Am Assoc Cancer Res 39:527, 1998
20. Britten CD, Hilsenbeck SG, et al.: Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-FU in the HT29 human colon xenograft model. Cancer Res 59:1049, 1999
21. Kelner MJ, McMorris TC, et al.: Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan. Leukemia 14:136, 2000
22. Weitman S, Barrera H, et al.: MGI 114: Augmentation of antitumor activity when combined with topotecan. J Pediat Hematology/Oncology 22(4):306, 2000